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Transdisciplinary/Holistic system needed where causality unclear
Reductionism strongly reflects a certain perspective on causality
Complex Genetic interplay versus unclear Environment 
High Fat and 
Carbohydrate Diet
Brit Med J Jankowski et al, 2010 
Making sense of Barrett's oesophagus; 
doing more for the few
Bennett C et al,  Am J Gastroenterol. 2015;110:662-682
Who?

Pre-Endoscopy - Screening
BOSS Trial (CI H Barr) awaited in 2021 for efficacy of surveillance
How?





GI Disease No. SNPs currently identified
IBD ~ 165
Colorectal Cancer ~ 30
Coeliac Disease ~ 20
Barrett’s Oesophagus 16
Oesophageal Adenocarcinoma 16 + 1 (independent of BE)
Environmental Component: High Sugar, Salt, Fat, Alcohol and Cigarettes
transcription factor 7-like 
2 (TCF7L2)
APOE
NOD2
So how do we fix the clinical problems now?
AspECT Trial (CI J Jankowski) will report 2017
• Patients with Barrett's esophagus, approximately 2 percent 
will die of esophageal cancer.
• Patients with Barrett's esophagus died more frequently of 
other causes, such as ischemic heart disease and 
pneumonia.
• Therefore need for adequate weight, diet, smoking and 
alcohol modification strategies.
• Need for better quality endoscopy and perhaps FNE in 
select centers in the community. 
Why?
Summary
• Who
60 years (men)
Obese
Smokers/alcohol
Long standing heartburn
• How
Quality endoscopy
Unsedated TNE
• Why
Increase global health benefits CVS and cancer deaths
Decrease burden and cost of BE surveillance
Cumbria recruiting now;  contact jjankowski@uclan.ac.uk
